`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 1 of 105 Page|D# 20742
`
`
`
`EXHIBIT A
`
`EXHIBIT A
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 2 of 105 PageID# 20743
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Trial Exhibit
`Ending Bates
`Beginning Bates
`No.
`RJREDVA_001485761
`RJREDVA_001485751
`RX‐0001
`RJREDVA_001626541
`RJREDVA_001626527
`RX‐0002
`RJREDVA_001642779
`RJREDVA_001642770
`RX‐0003
`RJREDVA_001642445
`RJREDVA_001642420
`RX‐0004
`RJREDVA_001642462
`RJREDVA_001642446
`RX‐0005
`RX‐0006 DEF_PUB_EDVA000014678 DEF_PUB_EDVA000014889
`
`RX‐0007 DEF_PUB_EDVA000015567 DEF_PUB_EDVA000016366
`
`RX‐0008 DEF_PUB_EDVA000014890 DEF_PUB_EDVA000015566
`
`RX‐0009 DEF_PUB_EDVA000016367 DEF_PUB_EDVA000018530
`
`RX‐0010 DEF_PUB_EDVA000018531 DEF_PUB_EDVA000019660
`
`Document Description
`U.S. Pat. No. 6,803,545 (Blake)
`U.S. Pat. No. 10,104,911 (Thorens)
`U.S. Pat. No. 9,814,265 (Rinker)
`U.S. Pat. No. 10,420,374 (Liu)
`U.S. Pat. No. 10,555,556 (Malgat)
`File History for U.S. Patent Application No. 10/161,639 (U.S. Pat.
`No. 6,803,545)
`File History for U.S. Patent Application No. 13/990,067 (U.S. Pat.
`No. 10,104,911)
`File History for U.S. Patent Application No. 14/344,026 (U.S. Pat.
`No. 9,814,265)
`File History for U.S. Patent Application No. 14/793,453 (U.S. Pat.
`No. 10,420,374)
`File History for U.S. Patent Application No. 15/117,663 (U.S. Pat.
`No. 10,555,556)
`File History for U.S. Pat. No. 9,072,321
`Stipulation (Joint) re: Authentication of 3rd Party Documents
`Joint Pre‐Trial Stipulation, 4‐9‐21
`Joint Stipulation of Uncontested Facts dated May 21, 2021
`
`RX‐0011
`RX‐0012
`RX‐0013
`RX‐0014
`RX‐0015 to
` RX‐0019
`(NOT USED)
`RX‐0020
`
`RX‐0021
`(NOT USED)
`RX‐0022
`
`RX‐0023 to
`RX‐0024
`(NOT USED)
`
`1199_RESP00010301
`
`1199_RESP00010422
`
`FDA PMTA Coversheet: Technical Project Lead Review (TPL)
`PMP SA 5/15/17
`
`1199_RESP00010463
`
`1199_RESP00010465
`
`CDC Press Release: "Cigarette Smoking Among U.S. Adults Hits
`All‐Time Low" (November 14, 2019)
`
`1
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 3 of 105 PageID# 20744
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Trial Exhibit
`No.
`RX‐0025
`
`Beginning Bates
`1199_RESP00010602
`
`Ending Bates
`1199_RESP00010603
`
`Document Description
`Law 360 (April 6, 2020) ‐ E‐Cigarette Deadline Extended Amid
`COVID‐19 Pandemic
`
`RX‐0026 to
`RX‐0029
`(NOT USED)
`RX‐0030
`
`RX‐0031 to
`RX‐0032
`(NOT USED)
`RX‐0033
`
`RX‐0034
`(NOT USED)
`RX‐0035
`
`RX‐0036 to
`RX‐0038
`(NOT USED)
`RX‐0039
`
`RX‐0040 to
`RX‐0042
`(NOT USED)
`RX‐0043
`
`RX‐0044 to
`RX‐0047
`(NOT USED)
`
`1199_RESP00010627
`
`1199_RESP00010630
`
`MUSC: Hollings Cancer Center: Heat Not Burn and Other
`Products
`
`1199_RESP00010652
`
`1199_RESP00010658
`
`Filter, Rise of Heat‐Not‐Burn Products Coincides With Decrease
`in Cigarette Sales
`
`1199_RESP00010692
`
`1199_RESP00010694
`
`Reynolds American Inc. News Release: "Complete Premarket
`Tobacco Product Applications ‐ Vuse Vibe and Vuse Ciro Join
`Reynolds' Prior Vuse Solo Submission to FDA (April 15, 2020)
`
`1199_RESP00010890
`
`1199_RESP00010907
`
`Healthy Innovation, Safer Families: FDA's 2018 Strategic Policy
`Roadmap ‐ January 2018
`
`1199_RESP00010925
`
`1199_RESP00010931
`
`Vaping 360 ‐ McDonald: The First Vape PMTA Has Been
`Submitted to the FDA
`
`2
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 4 of 105 PageID# 20745
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Trial Exhibit
`No.
`RX‐0048
`
`Beginning Bates
`1199_RESP00011600
`
`Ending Bates
`1199_RESP00011619
`
`RX‐0049
`
`1199_RESP00011682
`
`1199_RESP00011696
`
`RX‐0050
`
`1199_RESP00011697
`
`1199_RESP00011818
`
`RX‐0051
`
`1199_RESP00011976
`
`1199_RESP00011995
`
`RX‐0052
`
`1199_RESP00012311
`
`1199_RESP00012323
`
`RX‐0053
`
`1199_RESP00012324
`
`1199_RESP00012403
`
`RX‐0054
`
`1199_RESP00012463
`
`1199_RESP00012464
`
`RX‐0055
`
`1199_RESP00012473
`
`1199_RESP00012476
`
`RX‐0056
`
`1199_RESP00012477
`
`1199_RESP00012480
`
`RX‐0057
`
`1199_RESP00012495
`
`1199_RESP00012495
`
`RX‐0058
`
`1199_RESP00012745
`
`1199_RESP00012748
`
`RX‐0059
`
`1199_RESP00012749
`
`1199_RESP00012752
`
`Document Description
`Submission to Tobacco Products Scientific Advisory Committee,
`"Modified Risk Tobacco Product Applications: Applications for
`IQOS system with Marlboro Heatsticks, IQOS system Marlboro
`Smooth Menthol Heatsticks, and IQOS system with Marlboro
`Fresh Menthol Heatsticks (ITC Ex. Nos. JX‐0026; CX‐0075; RX‐
`0302 )
`PMI Science ‐ Scientific Update for Smoke‐Free Products, June
`2018, Issue 5
`PMTA Coversheet: Technical Project Lead Review (TPL)
`5/15/2017
`What You Need to Know about Quitting Smoking, Advice from
`the Surgeon General (ITC Ex. No. RX‐0315)
`Letter from M.R Holman (FDA) to J. Walker (Philip Morris
`Products S.A.) re FDA review of MRTPAs
`FDA Scientific Review of Modified Risk Tobacco Product
`Application (MRTPA) Under Section 911(d) of the PD&C Act —
`Technical Project Lead, 12/5/16
`Channel New Asia, "BAT Says US Vaping Slowdown Will Lead to
`Slower Growth in e‐Cig Business" (November 27, 2019)
`R.J. Reynolds Tobacco Company: Guiding Principles & Beliefs
`(Website)
`Reynolds American: Harm Reduction,
`https://www.reynoldsamerican.com/how‐we‐innovate/harm‐
`reduction
`R.J. Reynolds Tobacco Company: Transforming Tobacco
`(Website)
`The Seattle Times, 10/6/2019: Philip Morris quietly brings IQOS
`to U.S. amid vaping uproar
`Vaping 360 ‐ McDonald, 5/1/2019: IQOS Approved by FDA:
`How will it Affect Vaping
`
`3
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 5 of 105 PageID# 20746
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Trial Exhibit
`No.
`RX‐0060
`
`Beginning Bates
`1199_RESP00012994
`
`Ending Bates
`1199_RESP00012997
`
`RX‐0061
`
`1199_RESP00012998
`
`1199_RESP00013000
`
`RX‐0062
`
`1199_RESP00013492
`
`1199_RESP00013496
`
`RX‐0063
`
`1199_RESP00014118
`
`1199_RESP00014169
`
`RX‐0064
`(NOT USED)
`RX‐0065
`
`1199_RESP00014487
`
`1199_RESP00014489
`
`RX‐0066
`
`1199_RESP00014490
`
`1199_RESP00014491
`
`RX‐0067
`RX‐0068
`
`1199_RESP00015205
`1199_RESP00016061
`
`1199_RESP00015335
`1199_RESP00016063
`
`RX‐0069
`
`1199_RESP00016064
`
`1199_RESP00016065
`
`RX‐0070
`
`1199_RESP00016066
`
`1199_RESP00016068
`
`RX‐0071
`
`1199_RESP00016069
`
`1199_RESP00016070
`
`Document Description
`Reynolds American Inc. News Release: "Reynolds Completes
`2020 PMTA Submissions with Vuse Alto E‐Cigarette
`Applications" (September 4, 2020)
`Reynolds American Inc. News Release: "Reynolds Submits
`Second and Third Complete Premarket Tobacco Product
`Applications, Vuse Vibe and Vuse Ciro Join Reynolds' Prior Vuse
`Solo Submission to FDA" (April 15, 2020)
`NACS Daily ‐ Reynolds Completes 2020 PMTA Submissions
`(9/8/2020)
`Enforcement Priorities for Electronic Nicotine Delivery Systems
`(ENDS) and Other Deemed Products on the Market Without
`Premarket Authorization (Revised) (Apr. 29, 2020),
`https://www.fda.gov/media/133880/download.
`
`RJRT Website: Guiding Principles and Beliefs ‐ Balancing the
`Desires of our Stakeholders (7/19/2020)
`RJRT Website: Harm Reduction (9/14/2020),
`https://rjrt.com/tobacco‐use‐health/harm‐reduction/
`PMI Form 10‐K Annual Report for Fiscal Year end 12/31/2018
`Reynolds American.com: Harm Reduction,
`https://www.reynoldsamerican.com/how‐we‐innovate/harm‐
`reduction
`Contify Retail News, "Reynolds American Inc. Submits
`Premarket Tobacco Product Application for VUSE Products"
`(October 11, 2019)
`Mooresville Tribune, 10/11/2019: Reynolds applies to FDA for
`premarket status for Vuse e‐cigarette
`Impact Financial News, 9/10/2020: Reynolds Completes 2020
`PMTA Submissions
`
`4
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 6 of 105 PageID# 20747
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Trial Exhibit
`No.
`RX‐0072
`
`Beginning Bates
`1199_RESP00016071
`
`Ending Bates
`1199_RESP00016073
`
`RX‐0073
`
`1199_RESP00016076
`
`1199_RESP00016079
`
`RX‐0074
`
`1199_RESP00016082
`
`1199_RESP00016085
`
`RX‐0075
`
`1199_RESP00016086
`
`1199_RESP00016086
`
`RX‐0076
`
`1199_RESP00016312
`
`1199_RESP00016314
`
`RX‐0077
`
`1199_RESP00016448
`
`1199_RESP00016459
`
`RX‐0078
`
`1199_RESP50000280
`
`1199_RESP50000334
`
`RX‐0079
`
`1199_RESP50000750
`
`1199_RESP50000771
`
`RX‐0080
`
`1199_RESP50000931
`
`1199_RESP50000983
`
`RX‐0081
`RX‐0082
`
`1199_RESP50003229
`1199_RESP50003231
`
`1199_RESP50003230
`1199_RESP50003243
`
`Document Description
`Winston‐Salem Journal, 9/2/2020: Reynolds seeks approval for
`nicotine pouches; Reynolds seeks approval for nicotine pouches
`from FDA
`Reynolds Completes 2020 PMTA Submissions with Vuse Alto E‐
`Cig Applications, Sept. 4, 2020
`Winston‐Salem Journal, 9/4/2020 Craver: Reynolds Vapor
`completes submissions for nicotine products to FDA
`RJR Website: Our Vision and Mission ‐ Transforming Tobacco
`
`WSJ 9/9/2020 Maloney: Vaping Drops Among Young People In
`U.S.
`Zeller, Perspective: FDA's Preparations for September 9
`Deadline
`FDA: Premarket Tobacco Product Applications for Electronic
`Nicotine Delivery Systems, Guidance for Industry, June 2019
`
`Dai, Hongying, "Heated Tobacco Product Use and Associated
`Factors Among U.S. Youth, 2019," Drug and Alcohol
`Dependence (2020), available at
`https://doi.org/10.1016/j.drugalcdep.2020.108150
`FDA: Premarket Tobacco Product Applications for Electronic
`Nicotine Delivery Systems, DRAFT Guidance for Industry, May
`2016
`
`PM USA: Marketing Practices (10/22/2020)
`Philip Morris Products S.A., PMI Research & Development: IQOS
`owners EU: Key Methodological Features and Key Results (ITC
`Ex. No. CX‐0101)
`
`5
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 7 of 105 PageID# 20748
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Trial Exhibit
`No.
`RX‐0083
`
`Beginning Bates
`1199_RESP50003264
`
`Ending Bates
`1199_RESP50003285
`
`RX‐0084
`(NOT USED)
`RX‐0085
`
`ACU000031
`
`RX‐0086
`
`ACU000033
`
`ACU000032
`
`ACU000038
`
`Document Description
`Reuters Investigates: The Philip Morris Files, Clinical
`Complications Part 3, Former employees and contractors have
`detailed irregularities in the clinical experiments that underpin
`Philip Morris International's application to the FDA for approval
`of its IQOS smoking device by T. Lasseter, et al. (ITC Ex. No. CX‐
`0102)
`
`The Verge, E‐cigarettes linked to helping people quit smoking,
`by A. Chen 7‐26‐17
`Craver, Richard, "CDC Report Shows More Smokers Try to Quit
`with e‐Cigs Than Nicotine Replacement Products," Winston‐
`Salem Journal (April 18, 2017)
`
`RX‐0087 to
`RX‐0090
`(NOT USED)
`RX‐0091
`
`RX‐0092
`
`RX‐0093
`
`RX‐0094
`
`RX‐0095
`
`RX‐0096 to
`RX‐0098
`(NOT USED)
`
`ACU000069
`
`ACU000076
`
`ALTRIA_IQOS_EDVA0000000
`001
`ALTRIA_IQOS_EDVA0000000
`152
`ALTRIA_IQOS_EDVA0000000
`161
`ALTRIA_IQOS_EDVA0000000
`379
`
`ALTRIA_IQOS_EDVA0000000
`151
`ALTRIA_IQOS_EDVA0000000
`160
`ALTRIA_IQOS_EDVA0000000
`254
`ALTRIA_IQOS_EDVA0000000
`403
`
`Zhu, Shu‐Hong, et al., "E‐Cigarette Use and Associated Changes
`in Population Smoking Cessation: Evidence from US Current
`Population Surveys," BMJ 358 (2017)
`Intellectual Property License Agreement dated December 20,
`2018
`Intellectual Property Assignment dated 2/28/17
`
`Intellectual Property Purchase Agreement dated December 30,
`2016
`Draft IP Due Diligence Report dated 9/10/15
`
`6
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 8 of 105 PageID# 20749
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Beginning Bates
`ALTRIA_IQOS_EDVA0000000
`469
`ALTRIA_IQOS_EDVA0000000
`754
`ALTRIA_IQOS_EDVA0000000
`915
`
`Ending Bates
`ALTRIA_IQOS_EDVA0000000
`470
`ALTRIA_IQOS_EDVA0000000
`761
`ALTRIA_IQOS_EDVA0000000
`918
`
`Document Description
`Assignment from Wedegree GmbH to Philip Morris Products
`
`Intellectual Property Overview, dated 6/16/16
`
`Exclusivity Agreement with Altria Client Services LLC dated
`December 8, 2016
`
`Trial Exhibit
`No.
`RX‐0099
`
`RX‐0100
`
`RX‐0101
`
`RX‐0102 to
`RX‐0103
`(NOT USED)
`RX‐0104
`
`RX‐0105
`
`RX‐0106
`
`RX‐0107
`
`ALTRIA_IQOS_EDVA0000001
`188
`ALTRIA_IQOS_EDVA0000001
`209
`ALTRIA_IQOS_EDVA0000001
`688
`ALTRIA_IQOS_EDVA0000001
`705
`
`ALTRIA_IQOS_EDVA0000001
`194
`ALTRIA_IQOS_EDVA0000001
`210
`ALTRIA_IQOS_EDVA0000001
`689
`ALTRIA_IQOS_EDVA0000001
`705
`
`RX‐0108
`
`ALTRIA_IQOS_EDVA0000001
`706
`
`ALTRIA_IQOS_EDVA0000001
`707
`
`RX‐0109
`
`ALTRIA_IQOS_EDVA0000001
`720
`
`ALTRIA_IQOS_EDVA0000001
`721
`
`RX‐0110
`
`ALTRIA_IQOS_EDVA0000001
`737
`
`ALTRIA_IQOS_EDVA0000001
`738
`
`RX‐0111
`
`ALTRIA_IQOS_EDVA0000001
`751
`
`ALTRIA_IQOS_EDVA0000001
`753
`
`7
`
`Presentation: Minilogic/Smart Chip (HK) Intellectual Property
`Overview
`Controller Comparison
`
`IQOS PM USA Standard Variable Cost
`
`Assignment of U.S. Patent Application No. 14/793,453 from Loi
`Ying Liu to Smart Chip Microelectronic Co. Limited dated July
`22, 2015
`Notice of Recordation of Assignment of U.S. Patent Application
`No. 14/793,453 from Loi Ying Liu to Smart Chip Microelectronic
`Co. Limited dated July 22, 2015 (Reel: 036197, Frame: 0004‐
`0005)
`Assignment of Patent Application No. PCT/IB2014/063541 from
`Loi Ying Liu to Smart Chip Microelectronic Co. Limited dated
`August 22, 2014
`Assignment of Patent Application No. PCT/B2010/052949 from
`Loi Ying Liu to Minilogic Device Corporation Ltd. dated May 4,
`2011 (Reel: 026353, Frames: 0682‐0683)
`PM USA Incorporated ‐ Income Statement Consolidating Detail
`Segment
`
`
`
`Trial Exhibit
`No.
`RX‐0112
`
`RX‐0113
`
`RX‐0114
`
`RX‐0115
`(NOT USED)
`RX‐0116
`
`RX‐0117
`
`RX‐0118
`
`RX‐0119
`
`RX‐0120
`
`RX‐0121 to
`RX‐0122
`(NOT USED)
`RX‐0123
`
`RX‐0124
`
`RX‐0125 to
`RX‐0127
`(NOT USED)
`RX‐0128
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 9 of 105 PageID# 20750
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Beginning Bates
`ALTRIA_IQOS_EDVA0000001
`757
`ALTRIA_IQOS_EDVA0000001
`784
`
`Ending Bates
`ALTRIA_IQOS_EDVA0000001
`783
`ALTRIA_IQOS_EDVA0000001
`838
`
`ALTRIA_IQOS_EDVA0000001
`839
`
`ALTRIA_IQOS_EDVA0000001
`840
`
`ALTRIA_IQOS_EDVA0000005
`393
`ALTRIA_IQOS_EDVA0000005
`404
`ALTRIA_IQOS_EDVA0000005
`498
`ALTRIA_IQOS_EDVA0000005
`618
`ALTRIA_IQOS_EDVA0000005
`637
`
`ALTRIA_IQOS_EDVA0000005
`403
`ALTRIA_IQOS_EDVA0000005
`414
`ALTRIA_IQOS_EDVA0000005
`508
`ALTRIA_IQOS_EDVA0000005
`628
`ALTRIA_IQOS_EDVA0000005
`647
`
`Document Description
`IQOS Sales ‐ BW Reporting
`
`U.S. Settlement and License Agreement between Nu Mark LLC,
`Fontem Holdings 1 B.V. and Fontem Ventures B.V. dated
`December 23, 2016
`Fontem Payments (2017‐2020)
`
`Greensmartliving Disassembly and Electrical Test Report
`
`Disassembly and Electrical Test Report ‐ BLU
`
`GreenSmart Disassembly
`
`BLU Disassembly and Electrical Test Report
`
`Disassembly and Electrical Test Report ‐ LOGIC
`
`ALTRIA_IQOS_EDVA0000005
`880
`ALTRIA_IQOS_EDVA0000005
`907
`
`ALTRIA_IQOS_EDVA0000005
`887
`ALTRIA_IQOS_EDVA0000005
`909
`
`Presentation: Minilogic/Smart Chip (HK) Intellectual Property
`Overview
`Specification (Chinese)
`
`ALTRIA_IQOS_EDVA0000009
`036
`
`ALTRIA_IQOS_EDVA0000009
`049
`
`Presentation: Logic Power Series Evaluation
`
`8
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 10 of 105 PageID# 20751
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Beginning Bates
`
`Ending Bates
`
`Document Description
`
`ALTRIA_IQOS_EDVA0000009
`217
`
`ALTRIA_IQOS_EDVA0000009
`228
`
`Product Testing
`
`Trial Exhibit
`No.
`RX‐0129
`(NOT USED)
`RX‐0130
`
`RX‐0131
`(NOT USED)
`RX‐0132
`RX‐0133
`RX‐0134
`RX‐0135
`RX‐0136
`
`Altria_IQOS_ITC_00003808 Altria_IQOS_ITC_00003827
`Altria_IQOS_ITC_00005245 Altria_IQOS_ITC_00005286
`Altria_IQOS_ITC_00005287 Altria_IQOS_ITC_00005307
`Altria_IQOS_ITC_00015190 Altria_IQOS_ITC_00015227
`Altria_IQOS_ITC_00015536 Altria_IQOS_ITC_00015591
`
`RX‐0137
`RX‐0138
`RX‐0139
`RX‐0140
`RX‐0141
`RX‐0142
`
`Altria_IQOS_ITC_00015805 Altria_IQOS_ITC_00015869
`Altria_IQOS_ITC_00016826 Altria_IQOS_ITC_00016878
`Altria_IQOS_ITC_00023130 Altria_IQOS_ITC_00023139
`Altria_IQOS_ITC_00024254 Altria_IQOS_ITC_00024309
`Altria_IQOS_ITC_00028724 Altria_IQOS_ITC_00028758
`Altria_IQOS_ITC_00048576 Altria_IQOS_ITC_00048643
`
`Presentation: IQOS Purchaser Panel
`Presentation: IQOS Owners Panel Update
`IQOS Owners Panel
`Presentation: IQOS:
`Presentation: IQOS: Building a Brand Through Retail
`Experience
`IQOS Qualitative Short Home Use report
`Presentation: Consumer Journey KPI's
`Presentation: Jan. & Feb. 2020 Report
`Presentation: Smokeable Business Update
`Presentation: IQOS Learning Plan
`Commercial Engine Flowchart (11/18/2019 Altria PMI meeting)
`
`RX‐0143
`RX‐0144
`
`Altria_IQOS_ITC_00050996 Altria_IQOS_ITC_00051010
`Altria_IQOS_ITC_00054311 Altria_IQOS_ITC_00054430
`
`FDA 4/30/19 Marketing Order
`Presentation: Altria Board of Directors Meeting, February 2017
`
`RX‐0145
`RX‐0146
`RX‐0147
`RX‐0148
`RX‐0149
`
`Altria_IQOS_ITC_00055207 Altria_IQOS_ITC_00055257
`Altria_IQOS_ITC_00055258 Altria_IQOS_ITC_00055281
`Altria_IQOS_ITC_00055332 Altria_IQOS_ITC_00055352
`Altria_IQOS_ITC_00055602 Altria_IQOS_ITC_00055631
`Altria_IQOS_ITC_00069340 Altria_IQOS_ITC_00069354
`
`Presentation: Philip Morris USA, Product Portfolio Update
`Presentation: Philip Morris USA, iQOS Update
`Presentation: Philip Morris USA, iQOS Update
`IQOS Update Prepared for Engagement
`Presentation: Tobacco Products Three‐Year Plan Initiatives
`2020‐2022
`
`9
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 11 of 105 PageID# 20752
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Trial Exhibit
`No.
`RX‐0150
`
`Ending Bates
`Beginning Bates
`Altria_IQOS_ITC_00069459 Altria_IQOS_ITC_00069476
`
`RX‐0151
`RX‐0152
`RX‐0153
`RX‐0154
`RX‐0155
`RX‐0156
`RX‐0157
`
`Altria_IQOS_ITC_00074869 Altria_IQOS_ITC_00074914
`Altria_IQOS_ITC_00076398 Altria_IQOS_ITC_00076420
`Altria_IQOS_ITC_00078741 Altria_IQOS_ITC_00078784
`Altria_IQOS_ITC_00082212 Altria_IQOS_ITC_00082264
`Altria_IQOS_ITC_00082439 Altria_IQOS_ITC_00082473
`Altria_IQOS_ITC_00082474 Altria_IQOS_ITC_00082528
`Altria_IQOS_ITC_00082990 Altria_IQOS_ITC_00082990
`
`RX‐0158
`
`Altria_IQOS_ITC_00084821 Altria_IQOS_ITC_00084830
`
`RX‐0159
`
`Altria_IQOS_ITC_00085457 Altria_IQOS_ITC_00085485
`
`RX‐0160
`
`Altria_IQOS_ITC_00085487 Altria_IQOS_ITC_00085510
`
`RX‐0161
`RX‐0162
`RX‐0163
`RX‐0164
`RX‐0165
`RX‐0166
`RX‐0167
`RX‐0168
`RX‐0169
`RX‐0170
`RX‐0171
`
`Altria_IQOS_ITC_00085528 Altria_IQOS_ITC_00085529
`Altria_IQOS_ITC_00085748 Altria_IQOS_ITC_00085752
`Altria_IQOS_ITC_00085753 Altria_IQOS_ITC_00085768
`Altria_IQOS_ITC_00085769 Altria_IQOS_ITC_00085770
`Altria_IQOS_ITC_00086213 Altria_IQOS_ITC_00086217
`Altria_IQOS_ITC_00086218 Altria_IQOS_ITC_00086234
`Altria_IQOS_ITC_00086269 Altria_IQOS_ITC_00086273
`Altria_IQOS_ITC_00086478 Altria_IQOS_ITC_00086595
`Altria_IQOS_ITC_00086730 Altria_IQOS_ITC_00086735
`Altria_IQOS_ITC_00086930 Altria_IQOS_ITC_00086931
`Altria_IQOS_ITC_00087521 Altria_IQOS_ITC_00087538
`
`Document Description
`Sutanto, Edward, et al., "Prevalence, Use Behaviors, and
`Preferences Among Users of Heated Tobacco Products:
`Findings from the 2018 ITC Japan Survey," Int. J. Environ. Re.
`Public Health 16 , 4630 (2019)
`Presentation: IQOS Conversation 9/5/2019
`Presentation: IQOS 101 Product Overview
`Presentation: IQOS Overview
`Presentation: BOD Innovation Committee: IQOS Update
`Presentation: BOD Innovation Committee: IQOS Update
`Presentation: BOD Innovation Committee: IQOS Update
`Summary of Recent Analyst Comments on IQOS in the U.S.
`(draft)
`Presentation: Philip Morris USA, IQOS Cost Update (August
`2017)
`Presentation: Predicting Adult Smokers' Full Conversion to
`iQOS
`Presentation: Philip Morris USA, iQOS Update, Potentially
`Reduced Risk Products, May 13, 2016 (v.4)
`2017‐Dec‐21 Email from J. Murillo to M.R. Garnick
`Draft Presentation
`Presentation Slides ‐ U.S. Commercialization
`2018‐Jan‐12 Email from P.M. Miller to J.L. Murillo et al.
`Draft Presentation TPSAC
`Draft Presentation ‐ U.S. Commercialization
`Draft Presentation ‐ TPSAC
`Presentation: Restricting Access to Youth
`Presentation: IQOS Game Plan
`Draft Presentation ‐ TPSAC
`Presentation: U.S. Commercialization and Controls, Sarah
`Knakmuhs, Vice President, Heated Tobacco Products, Philip
`Morris USA
`
`10
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 12 of 105 PageID# 20753
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Trial Exhibit
`No.
`RX‐0172
`RX‐0173
`
`Ending Bates
`Beginning Bates
`Altria_IQOS_ITC_00089142 Altria_IQOS_ITC_00089142
`Altria_IQOS_ITC_00089367 Altria_IQOS_ITC_00089390
`
`RX‐0174
`RX‐0175
`
`Altria_IQOS_ITC_00089569 Altria_IQOS_ITC_00089606
`Altria_IQOS_ITC_00090448 Altria_IQOS_ITC_00090460
`
`RX‐0176
`
`Altria_IQOS_ITC_00090463 Altria_IQOS_ITC_00090481
`
`RX‐0177
`
`Altria_IQOS_ITC_00090484 Altria_IQOS_ITC_00090495
`
`RX‐0178
`
`Altria_IQOS_ITC_00090499 Altria_IQOS_ITC_00090536
`
`RX‐0179
`
`Altria_IQOS_ITC_00090717 Altria_IQOS_ITC_00090804
`
`RX‐0180
`
`Altria_IQOS_ITC_00090805 Altria_IQOS_ITC_00090914
`
`RX‐0181
`RX‐0182
`RX‐0183
`
`Altria_IQOS_ITC_00112128 Altria_IQOS_ITC_00112130
`Altria_IQOS_ITC_00112131 Altria_IQOS_ITC_00112148
`Altria_IQOS_ITC_00112149 Altria_IQOS_ITC_00112429
`
`RX‐0184
`
`Altria_IQOS_ITC_00112430 Altria_IQOS_ITC_00112534
`
`RX‐0185
`RX‐0186
`RX‐0187
`RX‐0188
`
`Altria_IQOS_ITC_00112620 Altria_IQOS_ITC_00112640
`Altria_IQOS_ITC_00112641 Altria_IQOS_ITC_00112652
`Altria_IQOS_ITC_00112672 Altria_IQOS_ITC_00112782
`Altria_IQOS_ITC_00113925 Altria_IQOS_ITC_00113951
`
`RX‐0189
`RX‐0190
`
`Altria_IQOS_ITC_00115539 Altria_IQOS_ITC_00115548
`Altria_IQOS_ITC_00116395 Altria_IQOS_ITC_00116403
`
`Document Description
`2015‐Dec‐18 Email from P.M. Miller to A.C. Viscarra
`Presentation: Philip Morris USA, Brand Management,
`Potentially Reduced Risk Products, Executive Leadership Team
`Update, February 2016
`Presentation: NGP Project Update (August 14, 2014)
`TPSAC Meeting on IQOS Tobacco Heating System as of 1/26/18
`at 12 pm
`TPSAC Meeting on IQOS Tobacco Heating System as of 1/25/18
`at 1 pm
`TPSAC Meeting on IQOS Tobacco Heating System as of 1/24/18
`at 5:30 pm
`TPSAC Meeting on IQOS Tobacco Heating System as of 1/25/18
`at 5 pm
`Tobacco Products Scientific Advisory Committee Meeting
`January 24, 2018
`Tobacco Products Scientific Advisory Committee Meeting
`January 25, 2018
`2017‐Nov‐3 Email from S.F. Knakmuhs to M.E. Manson et al
`TPSAC PMI Mock #1 Feedback Form ‐ 10/26/17
`Transcript of TPSAC PMI Mock Panel on October 26, 2017 in
`Washington, DC (full page)
`Transcript of TPSAC PMI Mock Panel on October 26, 2017 in
`Washington, DC (miniscript)
`Presentation: The IQOS Heating System
`Presentation: Population Modeling and Conclusion
`Presentation: Folder: Youth Restrict Access
`Amended and Restated NGP Distribution Agreement between
`Philip Morris International Management S.A. and Altria Client
`Services LLC dated July 15, 2015
`Presentation: IQOS Risk Assessment
`2018‐Jul‐16, 2018 FDA Information Request
`
`11
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 13 of 105 PageID# 20754
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Trial Exhibit
`No.
`RX‐0191
`
`Ending Bates
`Beginning Bates
`Altria_IQOS_ITC_00117711 Altria_IQOS_ITC_00117726
`
`RX‐0192
`RX‐0193
`RX‐0194
`RX‐0195
`
`RX‐0196
`RX‐0197
`RX‐0198
`
`Altria_IQOS_ITC_00117908 Altria_IQOS_ITC_00117911
`Altria_IQOS_ITC_00118574 Altria_IQOS_ITC_00118612
`Altria_IQOS_ITC_00121613 Altria_IQOS_ITC_00121647
`Altria_IQOS_ITC_00121652 Altria_IQOS_ITC_00121657
`
`Altria_IQOS_ITC_00121907 Altria_IQOS_ITC_00121912
`Altria_IQOS_ITC_00121913 Altria_IQOS_ITC_00121930
`Altria_IQOS_ITC_00122179 Altria_IQOS_ITC_00122226
`
`RX‐0199
`
`Altria_IQOS_ITC_00122227 Altria_IQOS_ITC_00122274
`
`RX‐0200
`
`Altria_IQOS_ITC_00122275 Altria_IQOS_ITC_00122324
`
`RX‐0201
`RX‐0202
`
`Altria_IQOS_ITC_00122354 Altria_IQOS_ITC_00122368
`Altria_IQOS_ITC_00122828 Altria_IQOS_ITC_00122841
`
`RX‐0203
`
`Altria_IQOS_ITC_00123268 Altria_IQOS_ITC_00123298
`
`RX‐0204
`(NOT USED)
`RX‐0205
`
`Altria_IQOS_ITC_00123443 Altria_IQOS_ITC_00123458
`
`RX‐0206
`
`Altria_IQOS_ITC_00124738 Altria_IQOS_ITC_00124780
`
`RX‐0207
`RX‐0208
`RX‐0209
`
`Altria_IQOS_ITC_00129866 Altria_IQOS_ITC_00129866
`Altria_IQOS_ITC_00136436 Altria_IQOS_ITC_00136440
`Altria_IQOS_ITC_00137473 Altria_IQOS_ITC_00137595
`
`Document Description
`Presentation: PMI R&D Technology & Operations, US Market ‐
`Device Evolution
`Presentation: TPSAC Transcript
`Presentation: IQOS Insights Plan
`Presentation: Regulatory Routes
`Summary of Meeting ‐ PMI and Altria, Switzerland, Feb. 12‐13,
`2015
`Response to March 19, 2019 FDA Information Request
`Response to August 20, 2018 FDA Information Request
`Presentation: IQOS, ALCS Regulatory Affairs, July 19, 2017,
`Altria Client Services
`Presentation: IQOS, ALCS Regulatory Affairs, July 19, 2017,
`Altria Client Services
`Presentation: IQOS, ALCS Regulatory Affairs, July 19, 2017,
`Altria Client Services
`Presentation: PMI R&D TPSAC Preparation
`Presentation: Heated Tobacco Products: Regulatory Science,
`Dr. Moira Gilchrist, Director of Scientific Engagement, Philip
`Morris International R&D, May 6, 2016
`Presentation: ELT Meeting Agenda, Aerosol Products Global
`Competitive Landscape
`
`Presentation: Update on E‐Vapor Category (July 2018), Altria
`Client Services
`Presentation: PM USA Business Update, February 14, 2020,
`Altria Client Services
`Presentation: IQOS ‐ International Market Comparison
`IQOS Core Messages
`Presentation: The IQOS Heating System ‐ Tobacco Products
`Scientific Advisory Committee, January 24, 2018
`
`12
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 14 of 105 PageID# 20755
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Ending Bates
`Beginning Bates
`Altria_IQOS_ITC_00137825 Altria_IQOS_ITC_00137934
`
`Altria_IQOS_ITC_00137977 Altria_IQOS_ITC_00138008
`
`Document Description
`Transcript of Tobacco Products Scientific Advisory Committee
`Meeting on January 24, 2018
`2018‐Aug‐13 Letter from M.L. Myers (Campaign for Tobacco‐
`Free Kids) to M. Zeller (FDA) re social media marketing of IQOS
`in the U.S. by PMI
`2018‐May‐24 Memo from B. Davis et al. to M. Gilchrist
`Presentation: IQOS Regulatory Overview, ALCS Regulatory
`Affairs, June 19, 2018, Altria Client Services
`Excel Spreadsheet: IQOS P&L Workbook
`Presentation: IQOS Scenario Planning, December 2017 Model
`Refresh (5/20/2020)
`10YP Model Comparison for IQOS
`Presentation: Philip Morris USA Brand Management, Atlanta
`Debrief, Potentially Reduced Risk Products, March 2016
`Project ‐ October 2018
`Presentation: Project, Key Insights & Next Steps, September
`2019, Altria Client Services
`Presentation: MRTPA ‐ Scenario Planning, Project Steering
`Committee
`Presentation: IQOS Conversation 9/5/2019 (draft)
`Presentation: Experience Altria, November 2, 2017
`Philip Morris International Press Release: "People Want
`Governments to Give Smokers Better Choices, Say Majority of
`31,000 People Polled in 31 Countries Worldwide" (October 11,
`2018)
`Presentation: PMI Key Market Data (May 20, 2020)
`Altria_IQOS_ITC_00160240 Altria_IQOS_ITC_00160248
`Extract re number of IQOS users
`Altria_IQOS_ITC_00160249 Altria_IQOS_ITC_00160252
`Presentation: IQOS , May 4, 2020, Altria Client Services
`Altria_IQOS_ITC_00160253 Altria_IQOS_ITC_00160300
`Altria_IQOS_ITC_00160519 Altria_IQOS_ITC_00160529 Organizational Chart for Reduced‐Risk Products on May 13,
`2017
`
`Altria_IQOS_ITC_00138028 Altria_IQOS_ITC_00138035
`Altria_IQOS_ITC_00138040 Altria_IQOS_ITC_00138072
`
`Altria_IQOS_ITC_00145165 Altria_IQOS_ITC_00145170
`Altria_IQOS_ITC_00145261 Altria_IQOS_ITC_00145289
`
`Altria_IQOS_ITC_00145359 Altria_IQOS_ITC_00145364
`Altria_IQOS_ITC_00146368 Altria_IQOS_ITC_00146388
`
`Altria_IQOS_ITC_00146712 Altria_IQOS_ITC_00146717
`Altria_IQOS_ITC_00146766 Altria_IQOS_ITC_00146776
`
`Altria_IQOS_ITC_00147019 Altria_IQOS_ITC_00147027
`
`Altria_IQOS_ITC_00153889 Altria_IQOS_ITC_00153925
`Altria_IQOS_ITC_00154257 Altria_IQOS_ITC_00154442
`Altria_IQOS_ITC_00158539 Altria_IQOS_ITC_00158540
`
`Trial Exhibit
`No.
`RX‐0210
`
`RX‐0211
`
`RX‐0212
`RX‐0213
`
`RX‐0214
`RX‐0215
`
`RX‐0216
`RX‐0217
`
`RX‐0218
`RX‐0219
`
`RX‐0220
`
`RX‐0221
`RX‐0222
`RX‐0223
`
`RX‐0224
`RX‐0225
`RX‐0226
`RX‐0227
`
`13
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 15 of 105 PageID# 20756
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Beginning Bates
`
`Ending Bates
`
`Document Description
`
`Altria_IQOS_ITC_00163979 Altria_IQOS_ITC_00164062
`
`Altria_IQOS_ITC_00163565 Altria_IQOS_ITC_00163602
`Altria_IQOS_ITC_00163832 Altria_IQOS_ITC_00163886
`
`PM USA IQOS Update June 2018
`Presentation: IQOS Overview, April 2018, Heated Tobacco
`Products
`Presentation: IQOS Commercialization Plan, Heated Tobacco
`Products (5/20/2020)
`IQOS Qualitative Short Home Use report
`Altria_IQOS_ITC_00169831 Altria_IQOS_ITC_00169895
`Eclipse Comparison to IQOS
`Altria_IQOS_ITC_00169896 Altria_IQOS_ITC_00169959
`IQOS Extended Home Use Test (e‐HUT) report,
`Altria_IQOS_ITC_00171443 Altria_IQOS_ITC_00171570
`2020‐Apr‐30 FDA Letter
`Altria_IQOS_ITC_00171818 Altria_IQOS_ITC_00171836
`Presentation: IQOS Business Update
`Altria_IQOS_ITC_00173229 Altria_IQOS_ITC_00173260
`PMI Research & Development Study Report
`Altria_IQOS_ITC_00173270 Altria_IQOS_ITC_00173543
`Presentation: IQOS Owners Panel Update
`Altria_IQOS_ITC_00183526 Altria_IQOS_ITC_00183553
`ALTRIA and PMPSA Points of Contact (June 26, 2019)
`Altria_IQOS_ITC_00194097 Altria_IQOS_ITC_00194100
`Altria_IQOS_ITC_00195962 Altria_IQOS_ITC_00195972 US Market Performance Update ‐ S&OP ‐ Feb 2020
`Altria_IQOS_ITC_00203001 Altria_IQOS_ITC_00203008
`Presentation: IQOS Performance Tracking 2/25/2020
`
`Trial Exhibit
`No.
`RX‐0228
`(NOT USED)
`RX‐0229
`RX‐0230
`
`RX‐0231
`
`RX‐0232
`RX‐0233
`RX‐0234
`RX‐0235
`RX‐0236
`RX‐0237
`RX‐0238
`RX‐0239
`RX‐0240
`RX‐0241
`RX‐0242
`(NOT USED)
`RX‐0243
`
`Altria_IQOS_ITC_00220533 Altria_IQOS_ITC_00220533
`
`RX‐0244
`RX‐0245
`
`Altria_IQOS_ITC_00265842 Altria_IQOS_ITC_00265842
`Altria_IQOS_ITC_00293233 Altria_IQOS_ITC_00293233
`
`RX‐0246
`RX‐0247
`
`Altria_IQOS_ITC_00298975 Altria_IQOS_ITC_00299001
`Altria_IQOS_ITC_00315806 Altria_IQOS_ITC_00315807
`
`RX‐0248
`
`Altria_IQOS_ITC_00315818 Altria_IQOS_ITC_00315822
`
`RX‐0249
`
`Altria_IQOS_ITC_00315828 Altria_IQOS_ITC_00315832
`
`14
`
`Blackwell, John Reid, "Accord System Updated, Philip Morris
`Continues Testing Sales," Richmond Times Dispatch
`Accord Cigarette print Ad, The Time is Right for Accord
`Strategies Overview Research & Development Ongoing
`Projects/Activities Ending After 31 Dec 2007
`PMI EHC Business Case
`2020‐04‐21 Letter from Linda Stalters (SARDAA) to Lisa R.
`Barton (ITC) with public interest comments
`Public Interest Comments of the American Vaping Association
`(April 22, 2020)
`2020‐Apr‐16 Letter from Clint Flanagan (Nextera Healthcare) to
`the ITC with public interest comments re Inv. No. DN 3447
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 16 of 105 PageID# 20757
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Trial Exhibit
`No.
`RX‐0250
`
`Ending Bates
`Beginning Bates
`Altria_IQOS_ITC_00315844 Altria_IQOS_ITC_00315848
`
`RX‐0251
`
`Altria_IQOS_ITC_00315849 Altria_IQOS_ITC_00315852
`
`RX‐0252
`
`Altria_IQOS_ITC_00315878 Altria_IQOS_ITC_00315882
`
`RX‐0253
`
`Altria_IQOS_ITC_00315890 Altria_IQOS_ITC_00315944
`
`RX‐0254
`RX‐0255
`
`Altria_IQOS_ITC_00315945 Altria_IQOS_ITC_00315946
`Altria_IQOS_ITC_00315953 Altria_IQOS_ITC_00315954
`
`RX‐0256
`
`Altria_IQOS_ITC_00315955 Altria_IQOS_ITC_00315956
`
`RX‐0257
`
`Altria_IQOS_ITC_00315957 Altria_IQOS_ITC_00315962
`
`RX‐0258
`RX‐0259
`RX‐0260
`
`Altria_IQOS_ITC_00316205 Altria_IQOS_ITC_00316211
`Altria_IQOS_ITC_00337245 Altria_IQOS_ITC_00337270
`Altria_IQOS_ITC_00345169 Altria_IQOS_ITC_00345218
`
`Document Description
`2020‐Apr‐16 Letter from Clint Flanagan (Nextera Healthcare) to
`the ITC with public interest comments re Inv. No. DN 3447
`2020‐Apr‐21 Letter from J.K. Gunther (Spark MD) to L.R. Barton
`(ITC) with public interest comments re Inv. No. DN 3447
`
`2020‐Apr‐9 ITC notice of receipt of complaint and solicitation of
`comments relating to public interest re 337‐TA‐1199
`2020‐Apr‐9 Letter from D. Maiorana (Jones Day) to L.R. Barton
`(USITC) with ITC Complaint (Docket No. 3447)
`Info on ITC Section 337 cases ‐ Background
`ITC Notice of Receipt of Complaint ‐ DN 3447, Federal Register,
`Vol. 85, No. 73 (April 15, 2020)
`ITC, Temporary Change to Filing Procedures, 85 Fed. Reg. 15798
`(March 19, 2020)
`Inv. No. 337‐TA‐1199, Complainants’ Statement on Public
`Interest (USITC April 9, 2020)
`Presentation: JUUL Labs, Financial, November 2018
`Presentation: JUUL, Sales & Marketing, November 15, 2018
`Russell, Christopher, et al., "Transitions in Cigarette Smoking
`Associated with Use of the JUUL Vaping Device Among 18,799
`Adults in the United States," CSUR Research & Consultancy
`
`RX‐0261
`RX‐0262
`RX‐0263
`RX‐0264
`RX‐0265
`RX‐0266
`(NOT USED)
`RX‐0267
`
`Altria_IQOS_ITC_00351721 Altria_IQOS_ITC_00351728
`Altria_IQOS_ITC_00351838 Altria_IQOS_ITC_00351848
`Altria_IQOS_ITC_00360224 Altria_IQOS_ITC_00360245
`Altria_IQOS_ITC_00360279 Altria_IQOS_ITC_00360286
`Altria_IQOS_ITC_00360287 Altria_IQOS_ITC_00360302
`
`Presentation: JUUL Services Updated
`Presentation: Juul Valuation
`IQOS Sales ‐ BW Reporting ‐ Thru July 2020
`Amendment No. 1 to Service Agreement
`Transactional Service Agreement
`
`Altria_IQOS_ITC_00360360 Altria_IQOS_ITC_00360411
`
`IQOS Sales ‐ BW Reporting, 2019‐2020 (pdf version of RX‐0270)
`
`15
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 772-1 Filed 07/02/21 Page 17 of 105 PageID# 20758
`REYNOLDS'S TRIAL EXHIBIT LIST AMENDED 7-2-21
`
`Trial Exhibit
`No.
`RX‐0268
`RX‐0269
`RX‐0270
`
`RX‐0271
`
`Ending Bates
`Beginning Bates
`Altria_IQOS_ITC_00360565 Altria_IQOS